e-mail AACR 2019 | ECS progastrin

Dear AACR 2019 Participant,


ECS-Progastrin, a Swiss company, today presents you a revolutionary new IVD test to bring more decision-making elements to physicians in order to help diagnostics, treatment follow-up and monitoring of relapses of their cancer patients.
This world-class breakthrough research innovation is based on the detection of circulating progastrin which is specifically released in blood by tumor cells during the early stages of cancer and throughout its course. 

 

As of today, we have worked on 15 types of cancer (including cancers for which there was no known biomarker), and we have detected progastrin in all of them.

Moreover, it has been shown that progastrin is essential for the survival of tumor stem cells and that its neutralization leads to "Tumor Reversion": The tumor cell becomes "normal-like", differentiates and dies (Prieur et al., 2017). 

Our IVD test, DxPG80, is currently marketed under an RUO label in the USA and a CE-IVD label elsewhere. Additionally, a new therapy project targeting tumor stem cells through progastrin is under development.

In order to introduce you to this new biomarker and our clinical developments, Dominique Joubert PhD, the pioneer of this project, together with Mr. Alexandre Prieur PhD, CSO, will be both present with the team at the AACR congress at booth #4360.

Do you want to know more and have a private appointment with them on our booth?

or

  • Call us on: +1 (562) 725 6711.

 

 

We invite you also to meet our experts at the POSTERS SESSIONS:

 

First Author: Manish Kohli - Mayo Clinic

April 1, 2019, 1:00 PM to 5:00 PM

First Author: A. Prieur - ECS Progastrin

April 1, 2019, 1:00 PM to 5:00 PM

First Author: Manish Kohli - Mayo Clinic

April 1, 2019, 1:00 PM to 5:00 P

 

We look forward to speaking with you at AACR 2019.

The ECS Progastrin team.

 

 

More informations :ECS-AACR2019.com

ECS Progastrin Lab

Chemin de la Meuniere 12,

Prilly (Lausanne), Vaud 1008, SWITZERLAND